Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 May 1;124(9):1938-1945.
doi: 10.1002/cncr.31296. Epub 2018 Feb 16.

Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California

Affiliations
Comparative Study

Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California

Gwendolyn Ho et al. Cancer. .

Abstract

Background: To the authors' knowledge, few population-based studies to date have evaluated the association between location of care, complications with induction therapy, and early mortality in patients with acute myeloid leukemia (AML).

Methods: Using linked data from the California Cancer Registry and Patient Discharge Dataset (1999-2014), the authors identified adult (aged ≥18 years) patients with AML who received inpatient treatment within 30 days of diagnosis. A propensity score was created for treatment at a National Cancer Institute-designated cancer center (NCI-CC). Inverse probability-weighted, multivariable logistic regression models were used to determine associations between location of care, complications, and early mortality (death ≤60 days from diagnosis).

Results: Of the 7007 patients with AML, 1762 (25%) were treated at an NCI-CC. Patients with AML who were treated at NCI-CCs were more likely to be aged ≤65 years, live in higher socioeconomic status neighborhoods, have fewer comorbidities, and have public health insurance. Patients treated at NCI-CCs had higher rates of renal failure (23% vs 20%; P = .010) and lower rates of respiratory failure (11% vs 14%; P = .003) and cardiac arrest (1% vs 2%; P = .014). After adjustment for baseline characteristics, treatment at an NCI-CC was associated with lower early mortality (odds ratio, 0.46; 95% confidence interval, 0.38-0.57). The impact of complications on early mortality did not differ by location of care except for higher early mortality noted among patients with respiratory failure treated at non-NCI-CCs.

Conclusions: The initial treatment of adult patients with AML at NCI-CCs is associated with a 53% reduction in the odds of early mortality compared with treatment at non-NCI-CCs. Lower early mortality may result from differences in hospital or provider experience and supportive care. Cancer 2018;124:1938-45. © 2018 American Cancer Society.

Keywords: acute myeloid leukemia (AML); complications; early mortality; epidemiology; health services; location of care.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Analysis cohort of patients with first primary acute myeloid leukemia in California.
Figure 2.
Figure 2.
60-day Mortality in hospitalized acute myeloid leukemia patients receiving chemotherapy by location of care, California, 1999–2014. *NCI-CC = National Cancer Institute designated cancer center

Similar articles

Cited by

References

    1. Deschler B, Lubbert M: Acute myeloid leukemia: epidemiology and etiology. Cancer 107:2099–107, 2006 - PubMed
    1. Walter RB, Othus M, Borthakur G, et al.: Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 29:4417–23, 2011 - PMC - PubMed
    1. Ferrara F, Schiffer CA: Acute myeloid leukaemia in adults. Lancet 381:484–95, 2013 - PubMed
    1. Hahn A, Giri S, Yaghmour G, et al.: Early mortality in acute myeloid leukemia. Leuk Res 39:505–9, 2015 - PubMed
    1. Higby DJ, Cohen E, Holland JF, et al.: The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 14:440–6, 1974 - PubMed

Publication types

MeSH terms

Substances